Home » Topics » BioWorld Science

BioWorld Science
RSS

Proof-of-concept data presented from PHYOX phase I study of DCR-PHXC in primary hyperoxaluria

Sep. 6, 2018

Kineta starts first-in-human study of LHF-535

Sep. 6, 2018

Colorectal cancer stem cells are made, not born: study

Sep. 6, 2018

Protein-tyrosine kinase 2 identified as a therapeutic target for Kawasaki disease

Sep. 6, 2018

Inhibiting mitochondrial RTK is breast cancer target

Sep. 6, 2018

New PARP-1 inhibitor presented for cancer

Sep. 5, 2018

Pieris initiates phase I trial of PRS-343 plus atezolizumab in HER2-positive solid tumors

Sep. 5, 2018

Elunate approved in China for colorectal cancer

Sep. 5, 2018

Turnstone Biologics and La Jolla Institute collaborate to develop new cancer immunotherapies

Sep. 5, 2018

Tesaro advances JASPER study of Zejula in NSCLC

Sep. 5, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...